AcquisitionOther
bluebird bio, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
bluebird bio, Inc. -> target · $0.0001
(“bluebird bio”) completed the previously announced separation of its oncology programs and portfolio, and certain related assets and liabilities, into a separate, independent, publicly traded company (the “Separation”).
Open source record (SEC) ↗